Search

Displaying results 11 - 20 of 58 in total
  1. Indication

    Completely resected Stage IV melanoma

    go.drugbank.com/conditions/DBCOND0160977
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  2. Indication

    Resected Esophageal Cancer

    go.drugbank.com/conditions/DBCOND0149150
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  3. Indication

    Urothelial Carcinoma

    go.drugbank.com/conditions/DBCOND0039277
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  4. Indication

    Completely resected Stage IIC melanoma

    go.drugbank.com/conditions/DBCOND0160975
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  5. Indication

    Primary Immune Deficiency Disorders (PIDD)

    go.drugbank.com/conditions/DBCOND0038807
    Drugs: Hyaluronidase (human recombinant)
  6. Indication

    Primary Immunodeficiency

    go.drugbank.com/conditions/DBCOND0034592
    Drugs: Hyaluronidase (human recombinant)
  7. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    [L13290,L13296] A subcutaneous formulation of daratumumab co-formulated with hyaluronidase-fihj is also approved for the treatment of adults with multiple myeloma.

  8. Indication

    Gastroesophageal Junction Cancer

    go.drugbank.com/conditions/DBCOND0043630
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  9. Indication

    Intermediate risk Advanced Renal Cell Cancer

    go.drugbank.com/conditions/DBCOND0127584
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  10. Indication

    Metastatic Cancer of the Gastroesophageal Junction (GEJ)

    go.drugbank.com/conditions/DBCOND0173127
    Drugs: Hyaluronidase (human recombinant) · Nivolumab